ADREVIEW

Brand name authorized in: Spain France United Kingdom United States

Active ingredients

The drug ADREVIEW contains one active pharmaceutical ingredient (API):

1 Iobenguane ¹²³I
UNII P2TH1XYZ84 - IOBENGUANE I-123

Iobenguane is similar in structure to the antihypertensive drug guanethedine and to the neurotransmitter norepinephrine (NE). Iobenguane is, therefore, largely subject to the same uptake and accumulation pathways as NE. Iobenguane accumulates in adrenergically innervated tissues such as the adrenal medulla, salivary glands, heart, liver, spleen and lungs as well as tumors derived from the neural crest. By labeling iobenguane with the isotope iodine 123, it is possible to obtain scintigraphic images of the organs and tissues in which the radiopharmaceutical accumulates.

Read about Iobenguane ¹²³I

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code
Group title
Classification
Iobenguane (123I)
V Various → V09 Diagnostic radiopharmaceuticals → V09I Tumour detection → V09IX Other diagnostic radiopharmaceuticals for tumour detection
Discover more medicines within V09IX01

Medication package inserts

Below package inserts are available for further reading:

Title
Type
Country
Structured Product Labeling (SPL/PLR)
US

Unique identifiers

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country
Identification scheme
Identifier(s)
ES
Centro de información online de medicamentos de la AEMPS
Identifier(s): 68722
FR
Base de données publique des médicaments
Identifier(s): 65884582
GB
Medicines & Healthcare Products Regulatory Agency
Identifier(s): 398499, 398503, 398506, 398510, 398514, 398517, 398526, 398529
US
FDA, National Drug Code
Identifier(s): 17156-235